Long Beach, Calif., Dec. 10, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based therapeutics to address global medical indications, announced today that data generated by StemoniX, Inc., using their proprietary microBrain® 3D platform, demonstrated that the proprietary analog of… Read More..

FDA removes clinical hold; Company may proceed with VIITAL™ study Company expects to initiate study in the first quarter of 2020 Primary endpoint confirmed as proportion of wounds with greater than 50% healing at 3 months vs control wounds Majority of potential subjects have been pre-screened for the study NEW YORK… Read More..

CBDVHS Also Displayed Superior Anti-Inflammatory Activity When Compared to CBD Indicating Potential Use in Diseases of the Retina Unlike CBD, CBDVHS was not Associated with Biomarkers Related to Elevation of Intraocular Pressure (IOP)  LONG BEACH, CA, Dec. 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (EMBI), a… Read More..